WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc., , announced today that it will host a conference call and webcast on Thursday, November 13, 2008, at 4:30 pm EST to review the Company's third quarter 2008 financial results and provide an update on recent corporate developments.
To access the live call, dial 877-675-4756 (domestic) or 719-325-4902 (international). The live webcast and replay access of the teleconference will be available on the Investors section of the Company's website at http://www.ilgenetics.com.
About Interleukin Genetics
Interleukin Genetics, Inc. is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit http://www.ilgenetics.com.
CONTACT: Media, Lisa Rivero of LaVoie Group for Interleukin Genetics,
+1-978-745-4200 ext. 106, lrivero@lavoiegroup.com; or Investors, Melanie
Friedman of Stern Investor Relations for Interleukin Genetics,
+1-212-362-1200, melanie@sternir.com
Web site: http://www.ilgenetics.com/
